PCSK9 and coronary artery disorder: In contrast, the loss-of-function PCSK9 variants, such as nonsense mutations (Y142X and C679X), have demonstrated the opposite effects, showing a 40% reduction in plasma LDL-C levels and a reduced risk of CHD (129, 130).